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Anesthesia recovery periodAbstract Introduction: Sugammadex is an efficient reversal agent at any time, after neuromuscu-
lar blockade. It provides complete reversal for light or deep block facilitating rapid airway control
and decreases anesthesia recovery period in outpatient surgeries in children.
Patient and methods: After ethical committee approval, informed consent and sample size calcula-
tion, 70 patients planned for outpatient total bilateral tonsillectomy were divided randomly into 2
groups. Group S (n= 35) received 2 mg/kg sugammadex to reversing NMB achieved by rocuro-
nium. Group N (n= 35) received 0.05 mg/kg neostigmine and atropine sulfate 0.01 mg/kg, and
extubation time (time from administration of reversal agent to time of extubation), train-of-four
ratio, time to reach train-of-four >0.9, and side effects were recorded.
Results: There was no significant difference in demographic variables. TOF ratio after reversing
was a statistically less in group S than in group N (p< 0.05). The time when TOF rate exceeded
0.9 and extubation time were less in group S than in group N with significant difference
(p< 0.05). No adverse effect was recorded in both groups.
Conclusions: Sugammadex has created a novel rapid, effective and reliable retrieval from NMB
with rocuronium in children undergoing tonsillectomy with no side effects.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tonsillectomy and adenoidectomy in considered one of the
most frequent surgeries carried out all over the world. Healthy
children undergoing such procedure may be associated with
considerable morbidity and death rate [1]. The anesthetic tech-nique use neuromuscular blockers associated with higher com-
plications than other techniques without them. This is due to
the development of postoperative residual neuromuscular
block, affecting ventilation, airway patency, and hypoxia [2].
The reversal of NMBs is done by acetyl-cholinesterase inhibi-
tors (neostigmine, edrophonium, or pyridostigmine). Undesir-
able side effects of cholinesterase inhibitors (bradycardia,
hypersalivation and bronchoconstriction) can avoided by mus-
carinic antagonists as atropine. However, side effects of mus-
carinic antagonists such as blurring of vision, mouth dryness,
and increase in heart rate may occur. Cholinesterase inhibitors
have difficulty in reversing deeper muscular paralysis [3].
Because of their mechanism of action is based upon the action
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blockade, NMBA is present at the motor end plate, but the
maximum increase in the amount of acetylcholine to compete
with NMBA is expressed [3]. Neostigmine is the most potent
and selective cholinesterase inhibitors and not selective as it
stimulates both nicotinic and muscarinic systems. Atropine is
used to avoid the concomitant side effects [4].
Sugammadex eliminates the effect of steroid formed non-
depolarizing muscle relaxants through binding to them. The
first study on sugammadex in volunteers is published in 2005
[5]. Sugammadex is an alternative reversal agent to NMB,
which was executed by cholinesterase inhibitor. Postoperative
residual NMB action and the muscarinic adverse effects are
not present with sugammadex, when used to reverse rocuro-
nium induced NMB [6].
Rapid action of Sugammadex attributed to the mechanism
of action differs from other reversal agents [7]. More pediatric
studies are needed for certification of its use in variety of
patients needed to increase the knowledge about the safety
and effective use of sugammadex [8]. So we aim to present
our use of sugammadex regarding dose and in side effects in
the pediatrics. Sugammadex has been used to reverse moderate
NMB in various studies and shown very good recovery of
motor power [9,10]. Compared with neostigmine administra-
tion (0.05 mg/kg), sugammadex recovery time was approxi-
mately 13 times faster [11].
2. Materials and methods
This prospective randomized single blind clinical trial in which
the participant and their guardian did not know the drug used,
was conducted at Zagazig University Hospital, between June
2015 and December 2015, after approval of our hospital ethi-
cal committee and written informed consent was obtained
from parents or guardian of 70 children.
2.1. The aim of the study
Our aim was to compare the efficacy of sugammadex and
neostigmine on reversing neuromuscular blockade in pediatric
patients undergoing outpatient tonsillectomy. The primary
outcome was to measure the train-of-four ratio after reversing
neuromuscular blockers. The secondary outcome is extubation
time.
2.2. Rationale
The use of neuromuscular blockers in children was associated
with higher complications due to the development of postoper-
ative residual neuromuscular block, affecting ventilation, air-
way patency, and hypoxia, side effects of cholinesterase
inhibitors (bradycardia, hypersalivation and bronchoconstric-
tion) and muscarinic antagonists such as blurring of vision,
mouth dryness, and increase in heart rate.
2.3. Randomization
Allocation of subject in one arm of study was done by using
physical method (coin): head for one group and tail for the
other, until one group is completed, after that all randomlyselected subjects will automatically be allocated to the remain-
ing group (randomization with balance).
Seventy healthy children (2–10 years) scheduled for total
bilateral tonsillectomy were included in this study, exclusion
criteria such as parent refusal, age less than 2 years or more
than 10 years, difficult intubation, any neuromuscular disease,
any metabolic disorder, known drug hypersensitivity, kidney
impairment, liver impairment, congenital heart disease and his-
tory of malignant hyperthermia were not included.
Patients received no premedication, when they attended
operating theater; basic monitoring was carried out by the fol-
lowing: ECG (HR), blood pressure cuff to record (MAP), and
capnography and SpO2 values. An intravenous cannula was
inserted in peripheral vein of the upper limb. Anesthesia was
started with fentanyl (1 mice/kg) analgesia, propofol (1–
2 mg/kg) and rocuronium (0.6 mg/kg) for intubation. Ventila-
tion was provided by facemask with 100% and their neuro-
muscular block was monitored in other limb using the TOF-
Watch SX (Organon, Dublin, Ireland), by stimulation of
the ulnar nerve and activity of the adductor pollicis muscle.
Two electrodes were positioned near the wrist and the ulnar
nerve till recovery to a TOF ratio of 0.9 and then maintained
with isoflurane.
Neuromuscular blocking effect was monitored clinically by
increase in respiration frequency and disruption to respiration
curve, and with the onset of muscular movements. Another
bolus dose of rocuronium, 0.2 mg/kg, was injected during sur-
gery. At end of procedure isoflurane was discontinued and
TOF monitoring started. On the reappearance of T2 in 1st
group (Group N), patients received reversal by neostigmine
(0.05 m/kg) and atropine sulfate 0.01 mg/kg according to body
weight. In 2nd group (Group S): reversal was by 2.0 mg/kg
sugammadex.
Two anesthesiologists were available during procedure: one
was in charge of anesthesia (induction, tracheal intubation,
reversal of muscle relaxant, extubation and recovery), while
the other was in charge of recording all variables. In both
groups the primary outcome was to evaluate recovery time
from neostigmine or sugammadex administration until recov-
ery of the TOF ratio to 0.9% was recorded and the secondary
outcome extubation time from reversal from NMB to extuba-
tion was recorded.
Adverse effects such as bradycardia, hypotension, arrhyth-
mia, nausea, vomiting, rash, or postoperative recurrence of
neuromuscular blockade were recorded and patients’ oxygen
saturation and breathing in the recovery area were monitored
for at least 2 h.
2.4. Statistical analysis
Sample Size: In study by Kara et al. 2014, TOF ratio at extu-
bation was 76.95 ± 31 in Neostigmine group versus 96.35
± 21.34 in Sugammadex group, at a power analysis of b-
error = 0.8 and a-error = 0.05, and 35 patients per study
group were needed as the appropriate sample size to find sig-
nificance difference between the studied drugs.
Continuous variables were checked for normality by using
Shapiro-Wilk test. Mann Whitney U test was used to compare
two groups of non-normally distributed data. Percent of cate-
gorical variables were compared using the Pearson’s Chi-
square test. All tests were two sided. p< 0.05 was considered
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Package for Social Science for windows version 18.0 (SPSS
Inc., Chicago, IL, USA), MedCalc for windows version 13
(MedCalc Software bvba, Ostend, Belgium) and Microsoft
Office Excel 2010 for windows (Microsoft Cor., Redmond,
WA, USA).
3. Results
Table 1 shows no statistical difference in the demographic data
and time of surgery of the studied groups.
Table 2 shows no significant differences between 2 groups
in time for applying neostigmine or sugammadex after the last
NMB and time from the last NMB to extubation. There was a
statistically non-significant difference in group S regarding
extubation time than group N (p< 0.05).
Table 3 shows no significant differences in TOF ratio before
reversing. TOF ratio after reversing was a statistically signifi-
cant in group S than in group N (p< 0.05). The time when
TOF rate exceeded 0.9 was less in group S with significant dif-
ference (p< 0.05).Table 1 Demographic data of the studied groups.
Demographic data Control group (N) (n= 35)
Age (years) 5.42 ± 2.23
Gender
Male 16 (45.7%)
Female 19 (54.3%)
Weight (kg) 15.24 ± 8.92
Time of surgery (min) 33.62 ± 8.51
Rocuronium (mg) 9.12 ± 5.34
n= Total number of patients in each group; quantitative data were expre
(percentage).
* Mann Whitney U test.
§ Chi-square test; p< 0.05 is significant.
Table 2 The times from last NMB, reversal agent administration t
Time C
(n
Time for applying neostigmine or sugammadex after the last NMB
(min)
25
Time from the last NMB to extubation (min) 29
Extubation time (min) 4.
n= Total number of patients in each group; quantitative data were expr
* Mann Whitney U test; p< 0.05 is significant.
Table 3 The TOF ratio evaluation.
TOF ratio Control group (N) (
TOF ratio before reversing 39.16 ± 20.65
TOF ratio after reversing 83.21 ± 1.16
The time when TOF rate exceeded 0.9 min 1.64 ± 2.59
n= Total number of patients in each group; quantitative data were expr
* Mann Whitney U test; p< 0.05 is significant.4. Discussion
High doses of NMB was administered in children to get the
same NMB relaxation as in adults, as children have a different
efficacy than adults because of larger extracellular area in chil-
dren than in adults, and the NMB creates lower plasma con-
centrations in children due to spread of NMB in the
extracellular area [12]. Sugammadex is completely different
mechanism from anticholinesterase. Its effects are independent
from acetylcholine concentration and nicotinic or genus Mus-
carinic sensory receptor. Sugammadex is effective particularly
on the steroid formed NMB such as rocuronium and vecuro-
nium [13]. It forms a cyclodextrin build with steroid NMB
relaxant being a reaper binder decreasing the NMB present
in plasma and in the nicotinic receptors. For this cause, the
side effects are noticed with muscarinic receptor affection with
anticholinesterase not presented with sugammadex [13].
We have used 2 mg/kg sugammadex, and assess the of
NMB effect with TOF after Sorgenfrei et al. [14] who com-
pared different doses of sugammadex with a placebo and
observed time to reach 0.90 TOF ratio was significantly shorterSugammadex group (S) (n= 35) p-value
5.64 ± 2.41 0.693*
17 (48.6%) 0.811§
18 (51.4%)
14.42 ± 10.65 0.728*
31.97 ± 4.75 0.315*
8.64 ± 7.59 0.760*
ssed as the mean ± SD; qualitative data were expressed as a number
o Extubation.
ontrol group (N)
= 35)
Sugammadex group (S)
(n= 35)
p-value
.54 ± 21.36 25.84 ± 21.45 0.953*
.14 ± 20.34 26.23 ± 22.32 0.571*
21 ± 1.18 1.25 ± 0.59 <0.001*
essed as the mean ± SD.
n= 35) Sugammadex group (S) (n= 35) p-value*
32.54 ± 20.84 0.186
91.25 ± 0.56 <0.001*
0.41 ± 0.58 0.007*
essed as the mean ± SD.
450 M. El sayed, S. Hassanwith sugammadex doses larger than 2 mg /kg. Schaller et al.,
and Hogg et al., showed that doses larger than 2 mg/kg sugam-
madex are efficient [15,16]. TOF ratio is a reliable objective
method to assess residual NMB. Safety of spontaneous venti-
lation was approved when TOF ratio isP0.9, so we can guar-
antee normal muscle functions [17].
We compared neostigmine with sugammadex reverses the
medium NMB obtained with rocuronium; TOF ratio after
reversing was 91.25 ± 0.56 in sugammadex and 83.21 ± 1.16
in neostigmine group. The time to reach 0.90 TOF ratio in sug-
ammadex and neostigmine reversal was found to be 0.41
± 0.58 min in sugammadex group and 1.64 ± 2.59 in neostig-
mine group, in agreement with the study by Khuenl-Brady
et al. [18] who compared the time to reach 0.90 TOF ratio in
sugammadex and neostigmine reversal was found to be
1.4 min with sugammadex 4 mg/kg and 17.6 min with neostig-
mine in a randomized multicentre study where it was applied
to reverse the medium NMB obtained with rocuronium in
adults.
Blobner et al. [11] reported that 11% of patients in the
neostigmine group reached the 0.90 TOF ratio in 5 min and
98% of the patients in the sugammadex group using 2 mg/kg
reached the 0.90 TOF ratio in 5 min. Jones et al. [19] reported
that the time to reach 0.90 TOF ratio was 18 times shorter with
sugammadex than with neostigmine in routine reversal of deep
NMB. Plaud et al. [9] reported that sugammadex was 10 times
faster in efficiency. It is now accepted that sugammadex is
more effective than ordinary drugs, cholinesterase inhibitors
in the recovery of NMB with rocuronium [20,21]. Our observa-
tions in our study are supportive of the studies that extubation
time was found to be 1.25 ± 0.59 min in sugammadex group
and 4.21 ± 1.18 in neostigmine group making fast, easy and
safe NMB reversal, in agreement with the study by Kara
et al. [22].
No side effects were reported in both groups in agreement
with the study by Plaud et al. [8] who reported that sugam-
madex use in children group is effective, safe and reliable drug
without hypersensitivity findings with dosing 2 mg/kg.
5. Conclusion
Sugammadex has created a novel rapid, effective and reliable
retrieval from NMB with rocuronium in children undergoing
tonsillectomy with no side effects.
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